Unicycive Therapeutics, Inc.
UNCYHealthcareNASDAQBiotechnology · Last scanned Jul 22, 2026
Scan Results
Daily timeframeUnicycive Therapeutics, Inc., a clinical-stage biotechnology company, identifies, develops, and commercializes therapies for the treatment of kidney diseases in the United States. Valued at $155.9M, UNCY is a micro-cap name in its sector. It develops oxylanthanum carbonate, a lanthanum-based phosphate binding agent, which is for the treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI-494, a nicotinamide ester derivative and a selective ATP-sensitive mitochondrial potassium channel activator, which is in Phase I clinical trial for the treatment of acute kidney injury and pre-clinical stage for the treatment of chronic kidney disease.
Market Cap
$155.9M
Beta
1.79
P/E (TTM)
—
P/E (Fwd)
1.11
EPS (TTM)
$-2.35
EPS (Fwd)
$5.15
ROE
-163.1%
ROA
-40.6%
Cash
$54.6M
Total Debt
$815,000
Free CF
-$6.9M
52W Change
27.3%
Annual Financials
Cash vs Debt
Where UNCY stands vs its 150-day and 200-day moving averages
As of the July 6, 2026 close, UNCY finished 15.61% below its 150-day moving average ($6.79) and 8.61% below its 200-day moving average ($6.27). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is UNCY overbought or oversold?
At the July 6, 2026 close, UNCY's RSI(14) was 38.1, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $54.6M in cash and $815K in debt, UNCY maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. The company is burning cash, with free cash flow at -$6.9M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -163.1%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has pulled back from $951K (2022) to $0 (2025), a 100% decline worth watching.
A beta of 1.79 means UNCY is more volatile than average. Investors should be prepared for wider price swings relative to broader indices. With cash comfortably exceeding debt, UNCY has financial flexibility that may help navigate uncertain periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Unicycive Therapeutics, Inc. and its sector.